Clobazam
Clobazam, sold under the brand names Frisium, Onfi and others, is a benzodiazepine class medication that was patented in 1968. Clobazam was first synthesized in 1966 and first published in 1969. Clobazam was originally marketed as an anxioselective anxiolytic since 1970, and an anticonvulsant since 1984. The primary drug-development goal was to provide greater anxiolytic, anti-obsessive efficacy with fewer benzodiazepine-related side effects.
Clinical data | |
---|---|
Trade names | Frisium, Urbanol, Onfi, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a612008 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Benzodiazepine |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 87% (oral) |
Protein binding | 80–90% |
Metabolism | Liver |
Metabolites |
|
Onset of action | 0.5–4 hours |
Elimination half-life |
|
Excretion | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.040.810 |
Chemical and physical data | |
Formula | C16H13ClN2O2 |
Molar mass | 300.74 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.